Effect of Combine Therapy by Mometasone Furoate and Azelastine with Single Therapy by Mometazone Furoate or Azelastine on Adenoid Size and Obstructive Symptoms in Patients Referring to ENT Clinic

Effect and Comparison Between Combine Therapy by Mometasone Furoate and Azelastine with Single Therapy by Mometazone Furoate or Azelastine on Adenoid Size and Obstructive Symptoms in Patients Referring to ENT Clinic

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200612047740N1

Enrollment

Registered

2020-06-23

Start date

2020-07-05

Completion date

Unknown

Last updated

2020-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obstruction Symptoms and Size of Adenoid.

Interventions

Intervention 1: Intervention group A: Initially, personal consent is obtained from the patients. Then nasal spray of Mometasone is used in each nostril, 1 puff, twice a day (50 micro gram in each puff

Eligibility

Sex/Gender

All

Age

6 Years to 12 Years

Inclusion criteria

Inclusion criteria: 6 to 12 Years old Children With Hypertrophy of Adenoid Grade 3 and 4 According to Cassano Grading

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Obstructive Sleep Apnea. Timepoint: At the Beginning and End of 30 Days Treatment Duration. Method of measurement: Berlucchi Grading.;Night Snoring. Timepoint: At the Beginning and End of 30 Days Treatment Duration. Method of measurement: Berlucchi Grading.;Cough. Timepoint: At the Beginning and End of 30 Days Treatment Duration. Method of measurement: Berlucchi Grading.;Rhinorrhea. Timepoint: At the Beginning and End of 30 Days Treatment Duration. Method of measurement: Berlucchi Grading.;Nasal obstruction. Timepoint: At the Beginning and End of 30 Days Treatment Duration. Method of measurement: Berlucchi Grading.;Adenoid size/nasopharyngeal depth ratio. Timepoint: At the Beginning and End of 30 Days Treatment Duration. Method of measurement: Lateral Nasopharynx Radiography.	—

Measure

Time frame

Obstructive Sleep Apnea. Timepoint: At the Beginning and End of 30 Days Treatment Duration. Method of measurement: Berlucchi Grading.;Night Snoring. Timepoint: At the Beginning and End of 30 Days Treatment Duration. Method of measurement: Berlucchi Grading.;Cough. Timepoint: At the Beginning and End of 30 Days Treatment Duration. Method of measurement: Berlucchi Grading.;Rhinorrhea. Timepoint: At the Beginning and End of 30 Days Treatment Duration. Method of measurement: Berlucchi Grading.;Nasal obstruction. Timepoint: At the Beginning and End of 30 Days Treatment Duration. Method of measurement: Berlucchi Grading.;Adenoid size/nasopharyngeal depth ratio. Timepoint: At the Beginning and End of 30 Days Treatment Duration. Method of measurement: Lateral Nasopharynx Radiography.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactJamileh Haghirzavare

Esfahan University of Medical Sciences

jhaghirzavareh@gmail.com+98 31 3668 9801

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026